|Podcasts|July 22, 2021
Episode 87: Attacking Bladder Cancer From All Sides
Author(s)Elaine Quilici
Arthur Kuan, CEO of CG Oncology, talks about the present and future of bladder cancer therapies, and how he’s committed to making a difference.
Advertisement
Arthur Kuan, CEO of CG Oncology, discusses bladder cancer therapies and how his company is contributing to the fight.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
5
